Evidence map›Paper›PMID 24914134›Full record

ArticleBlood2014

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Bing Cui, Liguang Chen, Suping Zhang, Marek Mraz, Jessie-F Fecteau, Jian Yu, Emanuela M Ghia, Ling Zhang, Lei Bao, Laura Z Rassenti and 4 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02580552 (A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias), which is not on this map. Cited by 132 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 2 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02580552 phase1completednot on this mapstarted 2016, after this paper: background citation

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

TypeinterventionalSponsormiRagen Therapeutics, Inc.Ran2016 to 2020Enrolled66ConditionsCutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC SubtypeArmsCobomarsen
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. microRNA-155: a versatile noncoding RNA.Molecular biology reports · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Bing CuiMoores Cancer Center, University of California, San Diego, CA;
Liguang ChenMoores Cancer Center, University of California, San Diego, CA;
Suping ZhangMoores Cancer Center, University of California, San Diego, CA;
Marek MrazMoores Cancer Center, University of California, San Diego, CA; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; and.
Jessie-F FecteauMoores Cancer Center, University of California, San Diego, CA;
Jian YuMoores Cancer Center, University of California, San Diego, CA;
Emanuela M GhiaMoores Cancer Center, University of California, San Diego, CA;
Ling ZhangMoores Cancer Center, University of California, San Diego, CA;
Lei BaoMoores Cancer Center, University of California, San Diego, CA;
Laura Z RassentiMoores Cancer Center, University of California, San Diego, CA;
Karen MesserMoores Cancer Center, University of California, San Diego, CA;
George A CalinDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, of the CLL Research Consortium.
Carlo M CroceDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, of the CLL Research Consortium.
Thomas J KippsMoores Cancer Center, University of California, San Diego, CA;
University of California, San Diego · USClinical Research Consortium · USCentral European Institute of Technology – Masaryk University · CZ

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
ANTIBODY V GENE EXPRESSION IN B CELL CLLR37CA049870 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 1994 to 2013
$4.5M
NCI NIH HHS P01 CA081534NCI NIH HHS P01-CA81534NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA023100NCI NIH HHS R37 CA049870NCI NIH HHS R37-CA049870
6 · The paper itself

Abstract

High-level leukemia cell expression of micro-RNA 155 (miR-155) is associated with more aggressive disease in patients with chronic lymphocytic leukemia (CLL), including those cases with a low-level expression of ζ-chain-associated protein of 70 kD. CLL with high-level miR-155 expressed lower levels of Src homology-2 domain-containing inositol 5-phosphatase 1 and were more responsive to B-cell receptor (BCR) ligation than CLL with low-level miR-155. Transfection with miR-155 enhanced responsiveness to BCR ligation, whereas transfection with a miR-155 inhibitor had the opposite effect. CLL in lymphoid tissue expressed higher levels of miR155HG than CLL in the blood of the same patient. Also, isolated CD5(bright)CXCR4(dim) cells, representing CLL that had been newly released from the microenvironment, expressed higher levels of miR-155 and were more responsive to BCR ligation than isolated CD5(dim)CXCR4(bright) cells of the same patient. Treatment of CLL or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensitivity to BCR ligation, effects that could be blocked by inhibitors to miR-155. This study demonstrates that the sensitivity to BCR ligation can be enhanced by high-level expression of miR-155, which in turn can be induced by crosstalk within the tissue microenvironment, potentially contributing to its association with adverse clinical outcome in patients with CLL.

Indexed as

Gene Expression Regulation, LeukemicAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCalciumCD40 LigandCD5 AntigensFemaleFlow CytometryHumansInositol Polyphosphate 5-PhosphatasesLeukemia, Lymphocytic, Chronic, B-CellMaleMicroRNAsBiomarkers, TumorCalciumCD40 LigandCD5 AntigensInositol Polyphosphate 5-PhosphatasesMicroRNAsMIRN155 microRNA, humanPhosphoric Monoester HydrolasesReceptors, Antigen, B-CellReceptors, CXCR4RNA, MessengerZAP70 protein, humanZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID24914134
PMCPMC4110661
OpenAlexW2060013333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.